focus -WSS

focus

author：knowledge 2025-10-04 03:59:57 - browse：46

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： What to expect at HLTH 2023, the health care industry conference

knowledge

WSS

STAT Readout Newsletter: Today's biggest biotech updates

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Sana to lay off nearly a third of staff, de

FDA struggles to regulate food additives, sometimes for decades

The explosion of genetic testing requires a new approach

Pharmacists can make shortage drugs, but at what cost?

hotspot

focus

A Worst CEO gets some much-needed help

Wikipedia

Virginia high school admissions case could be legal follow

Studies point to risks of excluding people with obesity from drug trials

Jerome Adams on the need for new antivirals for Covid

Beam Therapeutics to lay off 20% of its staff, re

In age of alternative facts, a scholarly course on calling out crap

STAT Summit: Biotech founders on deal

Duchenne breakthrough therapy leaves behind pioneering families

What to expect at HLTH 2023, the health care industry conference

Hollywood unions extend contract negotiations for actors

FDA warns J&J's Abiomed: We will regulate your software

hotspot

How climate

Beam Therapeutics to lay off 20% of its staff, re

Analysis of telehealth claims data suggest service duplication

The future of health care in the House

FDA panel signals lack of confidence in Amgen cancer drug data

STAT Summit: Michael J. Fox on progress in Parkinson's research

focus

Wikipedia

knowledge

leisure time